26 completed. 26 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 26 | Completed 26 |
| Phase 2 | 2 | Completed 2 |
Follow Hyperuricemia: new trials by email Literature Review of Hyperuricemia trials Research Report on Hyperuricemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval repaglinide; midazolam; SHR4640, repaglinide; midazolam; SHR4640; SHR4640 placebo, repaglinide; midazolam; SHR4640 placebo - Gout and Hyperuricemia | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 24 | 2024-01-04 | 2024-03-06 |
| Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects SHR4640 - Hyperuricemia | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 34 | 2023-12-13 | 2024-01-23 |
| Effect of Tigulixostat on the Pharmacokinetics of Theophylline Tigulixostat, Theophylline - Gout, Hyperuricemia | Phase 1 | Completed | LG Chem | 24 | 2023-10-31 | 2024-01-03 |
| Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia dotinurad, dotinurad + allopurinol, allopurinol - Gout, Hyperuricemia | Phase 1 / Phase 2 | Completed | Urica Therapeutics Inc. | 20 | 2023-10-04 | 2026-06-10 |
| Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects SHR4640 - Hyperuricemia | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 16 | 2023-08-07 | 2024-07-11 |
| SAD,MAD and Food Effect Study of SAP-001 Tablets in Chinese Subjects SAP-001, Placebo - Gout, Hyperuricemia | Phase 1 | Completed | Shanton Pharma Co., Ltd. | 70 | 2023-05-29 | 2024-11-12 |
| A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels PRX-115, Placebo - Gout | Phase 1 | Completed | Protalix | 64 | 2023-03-23 | 2025-02-11 |
| A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia SIBP-R002, Dexamethasone or Methyl prednisolone, Diphenhydramine - Asymptomatic Hyperuricemia | Phase 1 | Completed | Shanghai Institute Of Biological Products | 45 | 2022-04-11 | 2023-12-27 |
| Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing with light meal, Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing in fasted/fed state - Hyperuricemia, Gout | Phase 1 | Completed | Allena Pharmaceuticals | 12 | 2022-01-11 | 2023-01-23 |
| Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults LC350189 Tablet, LC350189 Capsule - Gout, Hyperuricemia | Phase 1 | Completed | LG Chem | 23 | 2021-07-31 | 2022-01-06 |
| Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase) ALLN-346, Placebo - Hyperuricemia, Gout | Phase 1 | Completed | Allena Pharmaceuticals | 18 | 2021-04-21 | 2021-07-01 |
| A Safety and Tolerability Study of FCN-207 in Healthy Volunteers Placebo, fasted vs. high-fat meal - Hyperuricemia | Phase 1 | Completed | Fochon Pharmaceuticals, Ltd. | 132 | 2020-11-11 | 2024-08-05 |
| ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers ALLN-346, Placebo - Hyperuricemia | Phase 1 | Completed | Allena Pharmaceuticals | 24 | 2020-09-02 | 2021-07-23 |
| Mass Balance Study of [14C]LC350189 in Healthy Volunteers [14C] LC350189 - Gout, Hyperuricemia | Phase 1 | Completed | LG Chem | 6 | 2020-02-26 | 2020-06-26 |
| The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults Xanthine Oxidase Inhibitor, nonsteroidal anti-inflammatory drug - Gout, Hyperuricemia | Phase 1 | Completed | LG Chem | 24 | 2020-01-22 | 2020-06-26 |
| Renal PK Study of LC350189 LC350189 200 mg - Gout, Hyperuricemia | Phase 1 | Completed | LG Chem | 37 | 2019-11-19 | 2020-09-21 |
| The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults. Xanthine Oxidase Inhibitor - Gout, Hyperuricemia | Phase 1 | Completed | LG Chem | 24 | 2019-11-05 | 2020-06-26 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 ABP-671, Placebo - Hyperuricemia, Gout | Phase 1 | Completed | Atom Therapeutics Co., Ltd | 27 | 2019-09-05 | 2020-02-12 |
| D-0120 Safety and PK/PD Study in China D-0120 - Hyperuricemia or Gout | Phase 1 / Phase 2 | Completed | InventisBio Co., Ltd | 52 | 2019-04-18 | 2022-05-06 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects ABP-671, Placebo - Gout, Hyperuricemia | Phase 1 | Completed | Atom Therapeutics Co., Ltd | 32 | 2018-10-17 | 2020-07-29 |
Showing 20 of 26. Sign in to see all of them.
Gout (22)
Pathologic Processes (26) · Pathological Conditions, Signs and Symptoms (26) · Arthritis (22) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (22) · Crystal Arthropathies (22) · Genetic Diseases, Inborn (22) · Joint Diseases (22) · Metabolic Diseases (22) · Metabolism, Inborn Errors (22) · Musculoskeletal Diseases (22) · Nutritional and Metabolic Diseases (22) · Purine-Pyrimidine Metabolism, Inborn Errors (22) · Rheumatic Diseases (22)
ruzinurad (6) · Allopurinol (1) · Anti-Inflammatory Agents, Non-Steroidal (1) · Dexamethasone (1) · Diphenhydramine (1) · Midazolam (1) · Naproxen (1) · Theophylline (1) · dotinurad (1) · repaglinide (1)
LG Chem (6) · Jiangsu HengRui Medicine Co., Ltd. (5) · Allena Pharmaceuticals (3) · Atom Therapeutics Co., Ltd (2) · Shanton Pharma Co., Ltd. (2) · Atridia Pty Ltd. (1) · Fochon Pharmaceuticals, Ltd. (1) · InventisBio Co., Ltd (1) · LG Life Sciences (1) · Protalix (1) · SK Chemicals Co., Ltd. (1) · Shanghai Institute Of Biological Products (1) · Urica Therapeutics Inc. (1)
United States (12) · China (9) · South Korea (2) · Australia (1) · New Zealand (1) · United Kingdom (1)
Christine Tosone (1) · Christine Tosone, MS (1) · Christine Tosone, MS, RAC (1) · Danielle Armas, M.D. (1) · Danielle Armas, MD (1) · Huan Zhou (1) · Ji-Young Park, M.D., Ph.D. (1) · John M Hill, MD (1) · Kyung Sang Yu, MD, PhD (1) · Li Li (1) · Mark Marshall, Dr. (1) · Melanie Fein (1) · Peter Winkle (1) · Sam Salman, B.Sc.BMBS (1)